{"title":"Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitors","description":"","products":[{"product_id":"erdafitinib-3-mg","title":"Erdafitinib 3mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eErdafitinib is used for locally advanced or metastatic urothelial cancer, a cancer of the bladder or urinary tract, when the cancer has a susceptible FGFR3 gene change and has worsened after earlier systemic treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose range: 4mg to 9mg once daily; the usual starting dose is 8mg once daily, with possible increase to 9mg or reduction if needed.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547337146737,"sku":"52035","price":34.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_8f336164-6a66-4a46-b939-124cdc917f9b.png?v=1786419177"},{"product_id":"erdafitinib-4-mg","title":"Erdafitinib 4mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eErdafitinib is used for locally advanced or metastatic urothelial cancer, a cancer of the bladder or urinary tract, when the cancer has a susceptible FGFR3 gene change and has worsened after earlier systemic treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose range: 4mg to 9mg once daily; the usual starting dose is 8mg once daily, with possible increase to 9mg or reduction if needed.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547337179505,"sku":"52036","price":35.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_300dab45-fd32-4944-86fd-c263f13fa207.png?v=1786419190"},{"product_id":"erdafitinib-5-mg","title":"Erdafitinib 5mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eErdafitinib is used for locally advanced or metastatic urothelial cancer, a cancer of the bladder or urinary tract, when the cancer has a susceptible FGFR3 gene change and has worsened after earlier systemic treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose range: 4mg to 9mg once daily; the usual starting dose is 8mg once daily, with possible increase to 9mg or reduction if needed.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547337212273,"sku":"52037","price":36.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_98c18cfb-36b6-477b-b2d5-b4d075c7d71a.png?v=1786419206"},{"product_id":"pemigatinib-4-5-mg","title":"Pemigatinib 4.5mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003ePemigatinib is used for adults with previously treated cholangiocarcinoma that cannot be removed by surgery or has spread and has an FGFR2 fusion or rearrangement.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eIt is also used for myeloid or lymphoid cancers with an FGFR1 rearrangement when the disease has come back or cannot be controlled with standard treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose range: 4.5mg to 13.5mg once daily for 14 days followed by 7 days off; the usual starting dose is 13.5mg once daily on that schedule.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547339604337,"sku":"52112","price":111.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_4de01ca2-375d-464c-8233-464da45d971c.png?v=1786428426"},{"product_id":"futibatinib-4-mg","title":"Futibatinib 4mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eFutibatinib is used for adults with previously treated intrahepatic cholangiocarcinoma that cannot be removed by surgery or has spread and has an FGFR2 gene fusion or rearrangement.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose: 20mg once daily, with lower doses used if side effects occur.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547341570417,"sku":"52199","price":198.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_a533f5bc-f86b-4b45-882b-8a37957a0c5c.png?v=1786419346"},{"product_id":"infigratinib-25-mg","title":"Infigratinib 25mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eInfigratinib was previously used for adults with previously treated, unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, but its US approval was withdrawn in 2024, so current use depends on local approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose where still used under specialist direction: 125mg once daily for 21 days of each 28-day cycle, with lower doses used if side effects occur; local approval status should be checked.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547342553457,"sku":"52244","price":243.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_70761567-755a-49b9-805c-e8170b01a87a.png?v=1786419466"},{"product_id":"infigratinib-100-mg","title":"Infigratinib 100mg","description":"\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eInfigratinib was previously used for adults with previously treated, unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, but its US approval was withdrawn in 2024, so current use depends on local approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-US\"\u003eUsual adult dose where still used under specialist direction: 125mg once daily for 21 days of each 28-day cycle, with lower doses used if side effects occur; local approval status should be checked.\u003c\/span\u003e\u003c\/p\u003e","brand":"Find-A-Drug","offers":[{"title":"Default Title","offer_id":63547342586225,"sku":"52245","price":244.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/files\/meds-compressed_f4958d41-101b-43f3-8145-02e0941b77b6.png?v=1786419454"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/1371\/8385\/collections\/Yellow_and_Blue_Caps_84510b3e-1ff3-49dc-8bac-9202f8bacf73.jpg?v=1777780640","url":"https:\/\/find-a-drug.com\/collections\/fibroblast-growth-factor-receptor-fgfr-tyrosine-kinase-inhibitors.oembed","provider":"Find-A-Drug","version":"1.0","type":"link"}